bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer Says
November 5, 2015 11:00 AM ESTOppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.
Lam commented, "BLUE published six ASH abstracts this morning, three of which were focused on LentiGlobin in beta-thalassemia and sickle cell disease. Key updates disclosed in the abstracts include new data from additional patients treated in the Northstar and HBG-205... More
bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH Update
November 5, 2015 8:20 AM ESTbluebird bio (NASDAQ: BLUE) is plunging 13.6% in pre-open trading following an update at ASH.
From the company's press release this morning:
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced that data from its ongoing clinical... More
bluebird bio (BLUE) Bullish View Reiterate at Post Q3 and Ahead of ASH Abstract Data -Oppenheimer
November 5, 2015 6:38 AM ESTOppenheimer analyst Wendy Lam reiterated an Outperform rating and $162 price target on bluebird bio (NASDAQ: BLUE) following Q3 results.
Lam commented, "BLUE reported 3Q15 loss per share of ($1.18) and ended the quarter with $901.7M in cash, cash equivalents, and marketable securities; we have updated our... More
